Previous 10 | Next 10 |
Shares of Cogent Biosciences Inc. (NASDAQ:COGT) traded at a new 52-week high today of $13.82. Approximately 17.1 million shares have changed hands today, as compared to an average 30-day volume of 250,000 shares. Over the past year, Cogent Biosciences Inc. has traded in a range of $2.20 ...
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors Building a pipeline of multiple small molecule inhibitors targeting genetically defined diseases, includi...
CAMBRIDGE, Mass. and BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced details for its planned Virtual R&D In...
Cogent Biosciences press release (NASDAQ:COGT): Q4 Net Loss of $24.9M As of December 31, 2021, the company had cash and cash equivalents of $219.7 million. For further details see: Cogent Biosciences reports Q4 results
APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for April 8, 2022 Ended 2021 with $219.7 million in cash, sufficient to fund ...
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming po...
Cogent Biosciences Provides 2022 Corporate Guidance APEX, SUMMIT and PEAK bezuclastinib clinical trials all initiated and enrolling APEX preliminary clinical data readout expected in the first half of 2022 R&D investor event planned April 2022 to detail robust discov...
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference PR Newswire CAMBRIDGE, Mass. and BOULDER, Colo. , Nov. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developin...
Cogent Biosciences (NASDAQ:COGT): Q3 Net Loss of $19.1M Cash and cash equivalents of $202.9M Press Release For further details see: Cogent Biosciences reports Q3 results
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results Initiated SUMMIT, a Phase 2 clinical trial of bezuclastinib for Nonadvanced Systemic Mastocytosis (NonAdvSM) patients PEAK, a Phase 3 clinical trial of bezuclastinib and sunitinib ...
News, Short Squeeze, Breakout and More Instantly...
Cogent Biosciences Inc Com Company Name:
COGT Stock Symbol:
NASDAQ Market:
Cogent Biosciences Inc Com Website:
2024-07-06 14:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Admin...
2024-06-26 16:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...